PE20211604A1 - Anticuerpos de union a ilt4 - Google Patents

Anticuerpos de union a ilt4

Info

Publication number
PE20211604A1
PE20211604A1 PE2021000028A PE2021000028A PE20211604A1 PE 20211604 A1 PE20211604 A1 PE 20211604A1 PE 2021000028 A PE2021000028 A PE 2021000028A PE 2021000028 A PE2021000028 A PE 2021000028A PE 20211604 A1 PE20211604 A1 PE 20211604A1
Authority
PE
Peru
Prior art keywords
seq
nos
antibodies
ilt4
bind
Prior art date
Application number
PE2021000028A
Other languages
English (en)
Spanish (es)
Inventor
Diana Yuhui Chen
Andrew Rankin
Xiaodi Deng
Joseph Toth
Linda Liang
Michelle Minhua Han
Christine BEE
Hong-An Truong
Mark J Selby
Alan J Korman
Nils Lonberg
Guodong Chen
Richard Y Huang
Ekaterina G Deyanova
Original Assignee
Five Prime Therapeutics Inc
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc, Bristol Myers Squibb Co filed Critical Five Prime Therapeutics Inc
Publication of PE20211604A1 publication Critical patent/PE20211604A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2021000028A 2018-07-09 2019-07-08 Anticuerpos de union a ilt4 PE20211604A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862695600P 2018-07-09 2018-07-09
US201862744611P 2018-10-11 2018-10-11
PCT/US2019/040820 WO2020014132A2 (en) 2018-07-09 2019-07-08 Antibodies binding to ilt4

Publications (1)

Publication Number Publication Date
PE20211604A1 true PE20211604A1 (es) 2021-08-23

Family

ID=67551692

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000028A PE20211604A1 (es) 2018-07-09 2019-07-08 Anticuerpos de union a ilt4

Country Status (18)

Country Link
US (3) US11401328B2 (cg-RX-API-DMAC7.html)
EP (1) EP3820904A2 (cg-RX-API-DMAC7.html)
JP (3) JP7411627B2 (cg-RX-API-DMAC7.html)
KR (2) KR102916159B1 (cg-RX-API-DMAC7.html)
CN (2) CN113056483B (cg-RX-API-DMAC7.html)
AU (1) AU2019302454A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020027095A2 (cg-RX-API-DMAC7.html)
CA (1) CA3104530A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021000011A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021000044A2 (cg-RX-API-DMAC7.html)
IL (1) IL279894A (cg-RX-API-DMAC7.html)
MX (1) MX2021000009A (cg-RX-API-DMAC7.html)
MY (1) MY201995A (cg-RX-API-DMAC7.html)
PE (1) PE20211604A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100096XA (cg-RX-API-DMAC7.html)
TW (2) TW202428604A (cg-RX-API-DMAC7.html)
WO (1) WO2020014132A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202306641B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2812208T3 (es) * 2013-03-14 2021-03-16 Bristol Myers Squibb Co Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗-ilt4抗體及抗原結合片段
EP4219559A3 (en) 2017-12-22 2023-10-18 Jounce Therapeutics, Inc. Antibodies for lilrb2
MY201995A (en) 2018-07-09 2024-03-28 Five Prime Therapeutics Inc Antibodies binding to ilt4
JP2023510132A (ja) * 2019-12-20 2023-03-13 メルク・シャープ・アンド・ドーム・エルエルシー Pd-1アンタゴニスト、ilt4アンタゴニストおよび化学療法剤の組合せを使用して癌を治療する方法
CA3165532A1 (en) * 2020-02-05 2021-08-12 The Board Of Regents Of The University Of Texas System Novel lilrb2 antibodies and uses thereof
CA3181197A1 (en) 2020-05-01 2021-11-04 NGM Biopharmaceuticals, Inc Ilt-binding agents and methods of use thereof
CA3184184A1 (en) * 2020-05-20 2021-11-25 The Trustees Of Columbia University In The City Of New York Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
JP2023541656A (ja) * 2020-09-17 2023-10-03 メルク・シャープ・アンド・ドーム・エルエルシー 癌を治療するための抗ilt4抗体またはそれと抗pd-1抗体との組合せの投与レジメン
EP4232087A4 (en) * 2020-10-21 2024-10-09 Immune-ONC Therapeutics, Inc. NOVEL ANTI-LILRB2 ANTIBODIES AND DERIVED PRODUCTS
CA3213110A1 (en) * 2021-03-09 2022-09-15 Jounce Therapeutics, Inc. Methods for the treatment of cancer
CN117545773A (zh) * 2021-04-09 2024-02-09 塞德斯医疗公司 抗ilt4的抗体、双特异性抗ilt4/pd-l1抗体及其用途
TW202409088A (zh) * 2022-07-08 2024-03-01 中國商科望(蘇州)生物醫藥科技有限公司 抗lilrb2抗體及其用途
WO2024022462A1 (zh) * 2022-07-29 2024-02-01 盛禾(中国)生物制药有限公司 一种抗ilt4的单域抗体及其应用
AU2023328075A1 (en) * 2022-08-22 2025-04-03 Antengene Biologics Limited Novel anti-lilrb2 antibodies and uses thereof
AU2023337290A1 (en) * 2022-09-08 2025-03-13 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-ilt4 antibody and pharmaceutical use thereof
EP4628508A1 (en) 2022-12-09 2025-10-08 Biodlink Biopharm Co., Ltd. Anti-ilt4 antibody as well as preparation method therefor and use thereof
GB202309512D0 (en) * 2023-06-23 2023-08-09 Astrazeneca Ab Lilrb2 binding proteins and uses thereof

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
EP0948623B1 (en) 1996-12-06 2010-01-27 Schering Corporation Isolated mammalian monocyte cell genes; related reagents
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US6448035B1 (en) 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
AU6366999A (en) 1998-10-30 2000-05-22 Takeda Chemical Industries Ltd. Betacellulin protein-containing preparations
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6667175B1 (en) 1999-06-15 2003-12-23 The Trustees Of Columbia University Generation of antigen specific T suppressor cells for treatment of rejection
MXPA02001878A (es) 1999-08-23 2003-08-20 Dana Farber Cancer Inst Inc Moleculas b7-4 novedosas y usos de las mismas.
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
WO2003000199A2 (en) 2001-06-25 2003-01-03 The Trustees Of Columbia University In The City Of New York Ilt3 and ilt4-related compositions and methods
US20040241167A1 (en) 2001-06-25 2004-12-02 Nicole Suciu-Foca Ilt3 and ilt4-related compositons and methods
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
AU2002360376B2 (en) 2001-11-14 2006-05-18 Immunex Corporation Modulation of LIR function to treat rheumatoid arthritis
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
ATE480562T1 (de) 2002-10-15 2010-09-15 Facet Biotech Corp Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
KR100976076B1 (ko) 2003-05-22 2010-08-17 아보트 러보러터리즈 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
JP4762156B2 (ja) 2004-01-12 2011-08-31 アプライド モレキュラー エボリューション,インコーポレイテッド Fc領域変異体
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
US8207110B2 (en) 2004-09-03 2012-06-26 The Trustees Of Columbia University In The City Of New York ITL3 polypeptides and uses thereof
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EA010654B1 (ru) 2004-11-23 2008-10-30 Пи Ай Пи Ко., Лтд. Вмонтированная в стену распределительная коробка водоснабжения
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
WO2006081430A2 (en) 2005-01-27 2006-08-03 Five Prime Therapeutics, Inc. Leader sequences for directing secretion of polypeptides and methods for production thereof
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール,インク. Gitr結合分子およびその使用
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
ES2547463T3 (es) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
NZ568016A (en) 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
WO2007089945A2 (en) 2006-02-02 2007-08-09 The Trustees Of Columbia University In The City Of New York Treating diseases by targeting silt3
WO2008094176A2 (en) 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20100047232A1 (en) 2006-11-14 2010-02-25 Jasvinder Atwal Modulators of neuronal regeneration
KR20090082480A (ko) 2006-11-14 2009-07-30 제넨테크, 인크. 뉴런 재생의 조절인자
UY30776A1 (es) * 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
JP2008278814A (ja) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk アゴニスティック抗ヒトgitr抗体による免疫制御の解除とその応用
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
KR20100109923A (ko) 2007-12-11 2010-10-11 제넨테크, 인크. 뉴런 재생의 조정인자
AU2008353145B2 (en) 2008-01-03 2013-09-12 Universite D' Aix-Marseille Bitherapy and tritherapy used for treating an HIV-positive patient
WO2009100135A2 (en) 2008-02-04 2009-08-13 Medical College Georgia Research Institute, Inc. Hla-g compositions and methods of use thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
AU2009246443A1 (en) 2008-05-13 2009-11-19 Genentech, Inc. Anti-PirB antibodies
US20090285803A1 (en) 2008-05-13 2009-11-19 Jasvinder Atwal ANTI-PirB ANTIBODIES
EP2296789A1 (fr) 2008-05-29 2011-03-23 Saint-Gobain Centre de Recherches et d'Etudes Européen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US20110007023A1 (en) 2009-07-09 2011-01-13 Sony Ericsson Mobile Communications Ab Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device
IN2015DN02826A (cg-RX-API-DMAC7.html) 2009-09-03 2015-09-11 Merck Sharp & Dohme
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
AU2011207253B2 (en) 2010-01-20 2015-02-12 Merck Sharp & Dohme Corp. Anti-ILT5 antibodies and ILT5-binding antibody fragments
JP5947727B2 (ja) 2010-01-20 2016-07-06 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ilt5抗体およびilt5結合抗体断片による免疫調節
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
NO2694640T3 (cg-RX-API-DMAC7.html) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
AR086287A1 (es) 2011-05-05 2013-12-04 Baylor Res Inst Composicion inmunoestimulante, metodo
US9696312B2 (en) 2011-09-02 2017-07-04 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand
WO2013036282A2 (en) 2011-09-07 2013-03-14 The Trustees Of Columbia University In The City Of New York Downregulation of inflammatory micrornas by ilt3
RU2014117952A (ru) 2011-10-06 2015-11-20 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Антитела против sema4a человека, используемые для лечения заболевания
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
WO2014006063A2 (en) 2012-07-02 2014-01-09 Medizinische Universität Wien Complement split product c4d for the treatment of inflammatory conditions
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
FR3000966B1 (fr) 2013-01-11 2016-10-28 Biomerieux Sa Procede pour etablir in vitro un pronostic de severite chez un patient en choc septique
EP2970373A1 (en) 2013-03-12 2016-01-20 The Board of Trustees of The Leland Stanford Junior University Methods and compositions for inhibiting the effects of amyloid beta oligomers
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
WO2015179633A1 (en) * 2014-05-22 2015-11-26 Fred Hutchinson Cancer Research Center Lilrb2 and notch-mediated expansion of hematopoietic precursor cells
LT3148579T (lt) 2014-05-28 2021-05-25 Agenus Inc. Anti-gitr antikūnai ir jų panaudojimo būdai
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
GB201410520D0 (en) * 2014-06-12 2014-07-30 Univ London Queen Mary Antibody
US20170274003A1 (en) 2014-09-16 2017-09-28 The Board Of Trustees Of The Leland Stanford Junior University Blocking pirb upregulates spines and functional synapses to unlock visual cortical plasticity and facilitate recovery from amblyopia
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
ES2826566T3 (es) 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
EP3256163A4 (en) 2015-02-11 2018-10-10 University Health Network Methods and compositions for modulating lilr proteins
CA3218106A1 (en) * 2015-03-06 2016-09-15 The Board Of Regents Of The University Of Texas System Anti-lilrb antibodies and their use in detecting and treating cancer
CA2980460A1 (en) * 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
CA3025681A1 (en) 2016-06-03 2017-12-07 Invectys Anti hla-g specific antibodies
US20190248893A1 (en) * 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2018022881A2 (en) 2016-07-29 2018-02-01 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
JOP20190055A1 (ar) * 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
TWI796329B (zh) * 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗-ilt4抗體及抗原結合片段
EP4219559A3 (en) * 2017-12-22 2023-10-18 Jounce Therapeutics, Inc. Antibodies for lilrb2
EP3740224A4 (en) 2018-01-18 2022-05-04 Adanate, Inc. ANTI-LILRB ANTIBODIES AND THEIR USES
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
MY201995A (en) 2018-07-09 2024-03-28 Five Prime Therapeutics Inc Antibodies binding to ilt4
WO2020023268A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
JP2022501428A (ja) 2018-09-17 2022-01-06 アイカーン スクール オブ メディスン アット マウント シナイ 抗lilrb2抗体およびその使用の方法
BR112021005868A2 (pt) 2018-09-27 2021-10-19 Tizona Therapeutics Anticorpos anti-hla-g, composições compreendendo anticorpos anti-hla-g e métodos de uso de anticorpos anti-hla-g

Also Published As

Publication number Publication date
CN119390840A (zh) 2025-02-07
JP2026064999A (ja) 2026-04-14
CO2021000044A2 (es) 2021-04-19
JP2024045119A (ja) 2024-04-02
CL2024002051A1 (es) 2024-10-25
TWI819024B (zh) 2023-10-21
US12435136B2 (en) 2025-10-07
AU2019302454A1 (en) 2021-02-25
MY201995A (en) 2024-03-28
TW202428604A (zh) 2024-07-16
IL279894A (en) 2021-03-01
BR112020027095A2 (pt) 2021-03-30
JP7411627B2 (ja) 2024-01-11
US11401328B2 (en) 2022-08-02
KR102916159B1 (ko) 2026-01-23
MX2021000009A (es) 2021-03-09
WO2020014132A3 (en) 2020-02-20
KR20260023588A (ko) 2026-02-20
CN113056483B (zh) 2025-08-01
CN113056483A (zh) 2021-06-29
JP2022513420A (ja) 2022-02-08
CL2021000011A1 (es) 2021-05-24
US20230174647A1 (en) 2023-06-08
US20260125466A1 (en) 2026-05-07
WO2020014132A2 (en) 2020-01-16
JP7793587B2 (ja) 2026-01-05
SG11202100096XA (en) 2021-02-25
KR20210030405A (ko) 2021-03-17
TW202012438A (zh) 2020-04-01
US20200079848A1 (en) 2020-03-12
EP3820904A2 (en) 2021-05-19
ZA202306641B (en) 2024-11-27
CA3104530A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
AR126242A2 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
Zhang et al. Retargeting NK‐92 for anti‐melanoma activity by a TCR‐like single‐domain antibody
ZA201706740B (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
BR112019008861A2 (pt) anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3)
NZ777032A (en) Anti-nkg2a antibodies and uses thereof
SA519401370B1 (ar) الأجسام المضادة وحيدة النسيلة المبتكرة لبروتين الموت المبرمج (pd-1)
MX2023001791A (es) Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
MX2022000112A (es) Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3).
PE20200384A1 (es) Metodo de fabricacion de anticuerpos bispecificos, anticuerpos bispecificos y uso terapeutico de dichos anticuerpos
BR112019008859A2 (pt) anticorpos direcionados contra a morte programada 1 (pd-1)
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
AR102698A1 (es) Anticuerpos contra cd73 y sus usos
FI3525583T3 (fi) Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä
CL2021000011A1 (es) Anticuerpos de unión a ilt4
AR101829A1 (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
PE20130207A1 (es) Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
MX350983B (es) Raton de cadena ligera comun.
PE20191487A1 (es) Anticuerpos anti-gitr y metodos de uso de los mismos
MX2020013606A (es) Constructos de anticuerpos multiespecificos.
PE20220217A1 (es) Anticuerpos humanizados contra la region de la cadena beta de la 9na familia trbv9 del tcr humano, y sus metodos de uso
AR109683A1 (es) Anticuerpos contra el factor xi y sus usos
CL2018003072A1 (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
MX2023011788A (es) Anticuerpos contra ilt4, anticuerpo biespecifico anti-ilt4/pd-l1 y usos de los mismos.